Last Updated on April 11, 2024 by The Health Master
FDCs
In the realm of pharmaceuticals, the evaluation and regulation of Fixed Dose Combinations (FDCs) play a critical role in ensuring public health and safety.
The sub-committee constituted by the Drugs Technical Advisory Board (DTAB) has recently garnered attention for its forthcoming meeting scheduled on April 5, 2024.
This meeting aims to delve into the assessment of 16 FDCs previously flagged as irrational by the esteemed Prof. Kokate Committee. Let’s delve deeper into the significance of this meeting and its implications.
1. Background of the Issue
1.1 Prof. Kokate Committee Report
The genesis of the current deliberations can be traced back to the recommendations put forth by the Prof. Kokate Committee.
This committee identified 16 FDCs among the 294 under scrutiny, deeming them irrational.
1.2 Regulatory Response
In response to the findings of the Prof. Kokate Committee, the DTAB convened to examine the report and endorsed the need for further evaluation, particularly focusing on the flagged FDCs.
2. The Role of DTAB Subcommittee
2.1 Composition
The DTAB sub-committee, led by Dr. Nilima Kshirsagar, comprises experts in clinical pharmacology and regulatory affairs.
Their expertise is instrumental in evaluating the safety, efficacy, and rationality of pharmaceutical combinations.
2.2 Objectives of the Meeting
The upcoming meeting on April 5, 2024, serves as a platform for stakeholders to present their perspectives on the identified FDCs.
It provides an opportunity for comprehensive deliberation before the sub-committee makes further recommendations.
3. Stakeholder Engagement
3.1 Importance of Stakeholder Participation
Stakeholders, including manufacturers and regulatory bodies, hold valuable insights into the development and usage of FDCs.
Their active involvement enriches the deliberative process and ensures a holistic assessment.
3.2 Call for Participation
The FDC division of the Central Drugs Standard Control Organisation (CDSCO) has issued a call for stakeholders to attend the online meeting and present their viewpoints.
The absence of stakeholders may influence the committee’s decision-making process.
4. Evolution of Regulatory Oversight
4.1 Historical Context
The scrutiny of FDCs dates back to 2007 when concerns were raised regarding unapproved combinations in the market.
Subsequent regulatory actions, including directives for withdrawal and committee formations, underscore the evolving regulatory landscape.
4.2 Recommendations and Categorization
The categorization of FDCs into rational, requiring further data, and irrational reflects a nuanced approach to regulatory decision-making.
It emphasizes the importance of evidence-based assessments in determining the fate of pharmaceutical combinations.
5. Future Implications
5.1 Impact on Pharmaceutical Industry
The outcome of the deliberations holds significant implications for manufacturers and marketers of the identified FDCs.
Compliance with regulatory directives and alignment with rationality criteria are imperative for sustained market presence.
5.2 Public Health Considerations
The ultimate objective of regulatory oversight is to safeguard public health interests.
Rationalization of FDCs ensures that medications adhere to safety and efficacy standards, enhancing patient outcomes and confidence in healthcare interventions.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
DTAB’s Recommendations for Labeling of Excipients
DTAB: Impact of Nimesulide on Vultures and Its Implications for Human Health
DTAB: Prescription for Nicotine Replacement Therapies
DTAB advocates Bar Codes and QR Codes on Vaccine Products
DTAB recommends amendment to Pack Size provisions for Tablets and Capsules
DTAB: Examination of RMP requirement for sale of Cough Syrups
USFDA approval granted for Eslicarbazepine Acetate Tablets
CDSCO grants dual approval for Trastuzumab Deruxtecan
DTAB’s Recommendations for Labeling of Excipients
Ensuring Ethical Pharmaceutical Marketing Practices: A Comprehensive Analysis
Medical Device recall: USFDA classifies recall of this Medical Device as most serious
Revised Schedule M: The Role of Pharmaceutical Waste Management
Pharma Printers must come under the ambit of Drugs Act
How to stop Fake Medicine Business
Drug alert: 58 out of 1167 samples declared as NSQ in February 2024
Increase in Prices of 800 Essential Medicines Set to Take Effect from April 1
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
